Drugs / HDM-SPIRE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02150343 | Sep 2014 → Apr 2017 | allergic rhinitis | Circassia Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-11-11 | Niox | Results Circassia Interim Management Statement niox.com ↗
Positive outcome with excellent safety profile demonstrated for HDM-SPIRE; well tolerated by all subjects, with no treatment-related adverse events and no difference between HDM-SPIRE and placebo in change in asthma control status |
| 2014-06-13 | Niox | Results Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study niox.com ↗
Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today announces positive top-line results from a two-year follow-up of a phase IIb clinical study of HDM-SPIRE |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-11-11 | Niox | Circassia Interim Management Statement niox.com ↗ |
| 2014-06-13 | Niox | Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study niox.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM-SPIRE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02150343 ↗ |